Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.44 |
| ▸ | F2R | P25116 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25413679 | 0.87 | CYP3A4 (0.59) | TSHRTP53CYP3A4LTB4R2MEN1 | |
| SCHEMBL26313641 | 0.85 | KMT2A (0.45) | TSHRTP53CYP3A4GPBAR1F2R | |
| SCHEMBL25410846 | 0.84 | TSHR (0.46) | TSHRTP53CYP3A4F2RMEN1 | |
| SCHEMBL25414172 | 0.82 | TSHR (0.47) | TSHRTP53CYP3A4MEN1KMT2A | |
| SCHEMBL26313653 | 0.81 | TSHR (0.52) | TSHRTP53CYP3A4GPBAR1LTB4R2 | |
| SCHEMBL26313870 | 0.79 | TSHR (0.45) | TSHRTP53MEN1KMT2ANPC1 | |
| SCHEMBL1926647 | 0.77 | ADRA2C (0.53) | TSHRTP53GPBAR1ALDH1A1GLA | |
| SCHEMBL1926836 | 0.77 | ALDH1A1 (0.57) | TSHRTP53MEN1KMT2APOLB | |
| SCHEMBL530129 | 0.73 | TP53 (0.53) | TSHRTP53CYP3A4MEN1KMT2A | |
| SCHEMBL25412746 | 0.72 | CYP3A4 (0.50) | TSHRTP53CYP3A4F2RMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | NOS1, NOS3, NOS2 | TSHR 990/4885TP53 15/4885CYP3A4 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.